KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
Stock Stats
News
Novogen (KZIA) is now covered by Laidlaw. They set a "buy" rating and a $25.00 price target on the stock.
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform [TheStreet.com]
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [Yahoo! Finance]
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [TheStreet.com]
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 424B3 KAZIA THERAPEUTICS LTD
Form 6-K KAZIA THERAPEUTICS LTD For: Apr 15
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.